Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally robust stocks like Incyte Corp. (INCY), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) could contribute to the health and wealth of your portfolios. Read more….

StockNews.com

What Biden’s announcement of Medicare negotiating drug prices means

Democrats have long wanted to allow Medicare to negotiate drug prices, which it hopes will lead to lower prescription costs

The Independent UK

3M agrees to pay $6 billion to settle earplug lawsuits from U.S. service members

Chemical and consumer product manufacturer 3M has agreed to pay $6 billion to settle numerous lawsuits from U.S. service members who say they experienced hearing loss or other serious injuries from using earplugs made by the company

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Here are the first 10 drugs that Medicare will target for price cuts

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.

WEKU

Texas can now apply to import lower-priced Canadian medications

Texas joins a handful of states turn to the north for cheaper drugs. But feds have been slow to approve requests, three years after giving initial OK.

The Texas Tribune

CVS Launches Cordavis to Target Biosimilars Market

New CVS unit aims to cut your prescription costs by offering alternatives to branded drugs.

Kiplinger

Is Johnson & Johnson (JNJ) a Buy Before September Begins?

Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Vivek Ramaswamy says he wants Elon Musk to be his presidential adviser

Republican candidate and biotech entrepreneur names Twitter CEO when asked about potential advisers should he win election

The Guardian - US

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

StockNews.com

3 Medical Stocks Dominating the Industry

Thanks to the non-cyclical nature and the increasing demand for healthcare services, the healthcare industry should continue to brave most market challenges. Hence, it could be an opportune time to explore dominating medical stocks: Elevance Health (ELV), Centene Corp. (CNC), and Molina Healthcare (MOH), which might garner substantial returns for…

StockNews.com

3 Pharma Stocks With Promising Pipelines

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

StockNews.com

FTSE 100 bosses ‘given average pay rise of £500,000 in 2022’

CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation

The Guardian - UK

Buy-now-pay-later closure hits unfunded medicines

Businesses relying on the popular but contentious payments model are finding their operations increasingly difficult to stack up, reports Andrew Bevin.

Newsroom.co.nz

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

Salon

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

The Guardian - US

What is the abortion case in front of the US supreme court right now?

On Tuesday the justices heard oral arguments on a rightwing effort to roll back access to a key abortion pill

StockNews.com

Walgreens Boots Alliance (WBA), CVS Health (CVS), and Rite Aid (RAD): Buy, Hold or Sell?

With rising healthcare spending, the drugstore industry is poised to witness solid growth amid heightened demand. As a result, leading industry players CVS Health (CVS), Walgreens Boots Alliance (WBA), and Rite Aid (RAD) stand to benefit. However, should you Buy, Hold, or Sell these stocks? Keep reading to find out.

Get all your
news in one place.

100's of premium titles.
One news app.

Newslaundry

NDTV’s Jan Vishwas Act debate: Viewers should know if panelists have conflict of interest

Over the last decade, I have been advocating for revamping drug regulatory laws in India. I have encountered much opposition in the process – some from the pharmaceutical industry and a lot more from public health activists working on access to medicine, many of whom look at quality and price…

The Times of India

Captagon: $3 narcotic pill sold in the Gulf worries European officials

Europe is bracing for the possible influx of a drug that’s hooked the Middle East as political shifts and crackdowns in the Gulf spur producers in Syria and Lebanon to tap new markets.

StockNews.com

Which of These 3 Pharma Stocks Are a Buy?

The pharma industry is expected to experience substantial growth in the coming years with expanding global medical needs. So, which of these pharma stocks, Ipsen (IPSEY), Collegium Pharmaceutical (COLL), and SNDL (SNDL), are a buy now? Keep reading.

StockNews.com

Which of These 3 Medical Stocks Has the Better Growth Opportunities?

The medical sector is expected to grow amid steady demand and technological advancements. So, let's analyze which of these stocks, CVS Health (CVS), Walgreens Boots Alliance (WBA), and TRxADE HEALTH (MEDS), has the better growth opportunities.

Zenger

Supreme Court Halts Purdue Pharma’s $6B Settlement From A Challenge In A Lawsuit

The Supreme Court temporarily blocked a bankruptcy settlement by Purdue Pharma that would shield victims from civil lawsuits.

The Independent UK

Family of Henrietta Lacks files new lawsuit over cells harvested without her consent

The family of Henrietta Lacks has filed another lawsuit accusing a second company of unjustly profiting off her cells for generations

StockNews.com

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

1 … 45 46 47 48

People

Jennifer Walker Elrod

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Department of Justice

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.